Faeth Therapeutics, Inc.

FTHReported to SECin USCIK 0001829802Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 9. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 9
Form 4 lines at Faeth Therapeutics, Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
Vousden Karen H—Awardnothing paid25,000 sharesSep 15, 2026Vousden Karen Hnothing paidAward · Sep 15Award25,000Sep 15, 2026
Parikh Anand KiranPresident and CEOAwardnothing paid398,018 sharesJul 23, 2026Parikh Anand KiranPresident and CEOnothing paidAward · Jul 23Award398,018Jul 23, 2026
Craver JosiahPAOAwardnothing paid30,824 sharesJul 23, 2026Craver JosiahPAOnothing paidAward · Jul 23Award30,824Jul 23, 2026
STEPHENSON BRIAN CChief Financial OfficerOpen-market buy$14,532600 sharesJul 1, 2026STEPHENSON BRIAN CChief Financial Officer$14,532Buy · Jul 1Open-market buy600Jul 1, 2026
STEPHENSON BRIAN CChief Financial OfficerOpen-market buy$102,9604,400 sharesJul 1, 2026STEPHENSON BRIAN CChief Financial Officer$102,960Buy · Jul 1Open-market buy4,400Jul 1, 2026